Praluent (alirocumab)

P=N/A, N=4545, Completed, Sanofi | Active, not recruiting --> Completed

P2, N=420, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting

Cadd4 potently induces PCSK9 degradation in arterial tissues, mitigates atherosclerotic progression and improves plaque composition via lipid-independent inhibition of the NF-κB/TNF-α pathway. These findings underscore the therapeutic promise of Cadd4 as a candidate for managing atherosclerotic cardiovascular disease.

P4, N=60, Recruiting, University Medical Centre Ljubljana | Not yet recruiting --> Recruiting

He had been taking almonertinib for 26 months, hybutimibe for 3 months and alirocumab for 1 month prior to admission. Almonertinib is a moderately sensitive substrate of CYP3A4, thereby may elevate statin concentration and increase the likelihood of developing myopathy. For patients who need to take almonertinib and cholesterol-lowering drugs simultaneously, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and cholesterol absorption inhibitors (such as ezetimibe and hybutimibe) can be considered instead of atorvastatin for the reduction of cardiovascular events.

P=N/A, N=124, Active, not recruiting, Sanofi

P=N/A, N=2214, Active, not recruiting, Sanofi

P4, N=60, Not yet recruiting, University Medical Centre Ljubljana

P=N/A, N=5995, Not yet recruiting, Novartis Pharmaceuticals

P2, N=60, Active, not recruiting, Duke University | Trial completion date: Mar 2026 --> Nov 2026

P4, N=250, Recruiting, Medical University Of Vienna | Not yet recruiting --> Recruiting

P2, N=114, Completed, Stanford University | Active, not recruiting --> Completed